Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Ptc Therapeutics' Current Deferred Revenue changed N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is 58726.59% up from last year.
  • Ptc Therapeutics' Current Deferred Revenue amounted to $1.7 million in Q3 2025.
  • Over the past 5 years, Ptc Therapeutics' Current Deferred Revenue peaked at $12.8 million during Q1 2025, and registered a low of $214000.0 during Q1 2023.
  • Moreover, its 5-year median value for Current Deferred Revenue was $1.7 million (2025), whereas its average is $3.9 million.
  • In the last 5 years, Ptc Therapeutics' Current Deferred Revenue plummeted by 8173.08% in 2021 and then skyrocketed by 58726.59% in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Current Deferred Revenue stood at $1.9 million in 2021, then fell by 28.89% to $1.4 million in 2022, then crashed by 40.71% to $801000.0 in 2023, then surged by 587.27% to $5.5 million in 2024, then crashed by 69.28% to $1.7 million in 2025.
  • Its Current Deferred Revenue stands at $1.7 million for Q3 2025, versus $9.8 million for Q2 2025 and $12.8 million for Q1 2025.